Management of the psychological comorbidities of dermatological conditions: practitioners’ guidelines

References

• ConnorCJLiuVFiedorowiczJGExploring the physiological link between psoriasis and mood disordersDermatol Res Pract2015201540963726550011
   PubMedGoogle Scholar
• FerreiraBIAbreuJLReisJPFigueiredoAMPsoriasis and associated psychiatric disorders: a systematic review on etiopathogenesis and clinical correlationJ Clin Aesthet Dermatol2016963643
   PubMedGoogle Scholar
• KooJLebwohlAPsychodermatology: the mind and skin connectionAm Fam Phys2001641118731878
   PubMed Web of Science ®Google Scholar
• GuptaMAGuptaAKPsychodermatology: an updateJ Am Acad Dermatol1996346103010468647969
   PubMed Web of Science ®Google Scholar
• KooJYPhamCTPsychodermatology. Practical guidelines on pharmacotherapyArch Dermatol199212833813881550372
   PubMedGoogle Scholar
• LauplandKBValiquetteLDelusional infestationCan J Infect Dis Med Microbiol20162016909183827366186
   PubMed Web of Science ®Google Scholar
• BewleyAPLeppingPFreudenmannRWTaylorRDelusional parasitosis: time to call it delusional infestationBr J Dermatol2010163112
   PubMed Web of Science ®Google Scholar
• Al-HarbiMPrevalence of depression in vitiligo patientsSkinmed201311632733024517036
   PubMedGoogle Scholar
• DowlatshahiEAWakkeeMArendsLRNijstenTThe prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysisJ Invest Dermatol201413461542155124284419
   PubMed Web of Science ®Google Scholar
• FlemingPBaiJWPrattMSibbaldCLyndeCGulliverWPThe prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trialsJ Eur Acad Dermatol Venereol Epub2016912
   Web of Science ®Google Scholar
• GhajarzadehMGhiasiMKheirkhahSAssociations between skin diseases and quality of life: a comparison of psoriasis, vitiligo, and alopecia areataActa Med Iran201250751151522930385
   PubMedGoogle Scholar
• MuffadelAAbdelganiAPsychiatric comorbidity in patients with psoriasis, vitiligo, acne, eczema and group of patients with miscellaneous dermatological diagnosesOpen J Psychiatry20144168175
   Google Scholar
• NguyenCMBeroukhimKDaneshMJBabikianAKooJLeonAThe psychosocial impact of acne, vitiligo, and psoriasis: a reviewClin Cosmet Investig Dermatol20169383392
   PubMed Web of Science ®Google Scholar
• ShlyankevichJChenAJKimGEKimballABHidradenitis suppurativa is a systemic disease with substantial comorbidity burden: a chart-verified case-control analysisJ Am Acad Dermatol20147161144115025440440
   PubMed Web of Science ®Google Scholar
• DalgardFGielerUHolmJOBjertnessEHauserSSelf-esteem and body satisfaction among late adolescents with acne: results from a population surveyJ Am Acad Dermatol200859574675119119094
   PubMed Web of Science ®Google Scholar
• OnderdijkAJvan der ZeeHHEsmannSDepression in patients with hidradenitis suppurativaJ Eur Acad Dermatol Venereol201327447347822339940
   PubMed Web of Science ®Google Scholar
• SannaLStuartALPascoJAAtopic disorders and depression: findings from a large, population-based studyJ Affect Disord201415526126524308896
   PubMed Web of Science ®Google Scholar
• DalgardFJGielerUTomas-AragonesLThe psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countriesJ Invest Dermatol2015135498499125521458
   PubMed Web of Science ®Google Scholar
• RostenbergAJrThe role of psychogenic factors in skin diseasesArch Dermatol196081818614439342
   PubMedGoogle Scholar
• KurdSKTroxelABCrits-ChristophPGelfandJMThe risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort studyArch Dermatol2010146889189520713823
   PubMed Web of Science ®Google Scholar
• RappSRFeldmanSRExumMLFleischerABJrReboussinDMPsoriasis causes as much disability as other major medical diseasesJ Am Acad Dermatol1999413 Pt 140140710459113
   PubMed Web of Science ®Google Scholar
• BalievaFKupferJLienLThe burden of common skin diseases assessed with the EQ5D: a European multi-centre study in 13 countriesBr J Dermatol Epub20161229
   Web of Science ®Google Scholar
• BeattiePELewis-JonesMSA comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseasesBr J Dermatol2006155114515116792766
   PubMed Web of Science ®Google Scholar
• TollefsonMMFinnieDMSchochJJEtonDTImpact of childhood psoriasis on parents of affected childrenJ Am Acad Dermatol201776228628927865579
   PubMed Web of Science ®Google Scholar
• LeeMSLinRYLaiMSIncreased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort studyJ Am Acad Dermatol201470469169824411084
   PubMed Web of Science ®Google Scholar
• WuSHanJLiWQQureshiAAHypertension, antihypertensive medication use, and risk of psoriasisJAMA Dermatol2014150995796324990147
   PubMed Web of Science ®Google Scholar
• PerrottSBMurrayAHLoweJMathiesonCMThe psychosocial impact of psoriasis: physical severity, quality of life, and stigmatizationPhysiol Behav200070556757111111012
   PubMed Web of Science ®Google Scholar
• RichardsHLFortuneDGGriffithsCEMainCJThe contribution of perceptions of stigmatisation to disability in patients with psoriasisJ Psychosom Res2001501111511259795
   PubMed Web of Science ®Google Scholar
• TakeshitaJCallis DuffinKShinDBPatient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical settingJ Am Acad Dermatol201471463364124928705
   PubMed Web of Science ®Google Scholar
• MrowietzUKragballeKReichKDefinition of treatment goals for moderate to severe psoriasis: a European consensusArch Dermatol Res2011303111020857129
   PubMed Web of Science ®Google Scholar
• RichardsHLFortuneDGWeidmannASweeneySKGriffithsCEDetection of psychological distress in patients with psoriasis: low consensus between dermatologist and patientBr J Dermatol200415161227123315606519
   PubMed Web of Science ®Google Scholar
• ArnauRCMeagherMWNorrisMPBramsonRPsychometric evaluation of the Beck Depression Inventory-II with primary care medical patientsHealth Psychol200120211211911315728
   PubMed Web of Science ®Google Scholar
• SteerRACavalieriTALeonardDMBeckATUse of the Beck Depression Inventory for Primary Care to screen for major depression disordersGen Hosp Psychiatry199921210611110228890
   PubMed Web of Science ®Google Scholar
• DoerflerLAFelnerRDRowlisonRTRaleyPAEvansEDepression in children and adolescents: a comparative analysis of the utility and construct validity of two assessment measuresJ Consult Clin Psychol19885657697723192795
   PubMed Web of Science ®Google Scholar
• TimbremontBBraetCDreessenLAssessing depression in youth: relation between the Children’s Depression Inventory and a structured interviewJ Clin Child Adolesc Psychol200433114915715028549
   PubMed Web of Science ®Google Scholar
• KroenkeKSpitzerRLWilliamsJBThe PHQ-9: validity of a brief depression severity measureJ Gen Intern Med200116960661311556941
   PubMed Web of Science ®Google Scholar
• KungSAlarconRDWilliamsMDPoppeKAJo MooreMFryeMAComparing the Beck Depression Inventory-II (BDI-II) and Patient Health Questionnaire (PHQ-9) depression measures in an integrated mood disorders practiceJ Affect Disord2013145334134323021192
   PubMed Web of Science ®Google Scholar
• SchuttPEKungSClarkMMKoballAMGrotheKBComparing the Beck Depression Inventory-II (BDI-II) and Patient Health Questionnaire (PHQ-9) depression measures in an outpatient bariatric clinicObes Surg20162661274127826341087
   PubMed Web of Science ®Google Scholar
• SpitzerRLKroenkeKWilliamsJBLoweBA brief measure for assessing generalized anxiety disorder: the GAD-7Arch Intern Med2006166101092109716717171
   PubMed Web of Science ®Google Scholar
• SwinsonRPThe GAD-7 scale was accurate for diagnosing generalised anxiety disorderEvid Based Med200611618417213178
   PubMedGoogle Scholar
• ZigmondASSnaithRPThe hospital anxiety and depression scaleActa Psychiatr Scand19836763613706880820
   PubMed Web of Science ®Google Scholar
• BjellandIDahlAAHaugTTNeckelmannDThe validity of the Hospital Anxiety and Depression Scale. An updated literature reviewJ Psychosom Res2002522697711832252
   PubMed Web of Science ®Google Scholar
• SnaithRPThe Hospital Anxiety And Depression ScaleHealth Qual Life Outcomes200312912914662
   PubMedGoogle Scholar
• AshcroftDMLi Wan PoAWilliamsHCGriffithsCEQuality of life measures in psoriasis: a critical appraisal of their qualityJ Clin Pharm Ther19982353913989875689
   PubMed Web of Science ®Google Scholar
• AliFMCuevaACVyasJA systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasisBr J Dermatol Epub201667
   Google Scholar
• BasraMKSalekMSCamilleriLSturkeyRFinlayAYDetermining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further dataDermatology (Basel, Switzerland)201523012733
   PubMed Web of Science ®Google Scholar
• ChrenMMLasekRJQuinnLMMostowENZyzanskiSJSkindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsivenessJ Invest Dermatol199610757077138875954
   PubMed Web of Science ®Google Scholar
• BronsardVPaulCPreySWhat are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literatureJ Eur Acad Dermatol Venereol201024Suppl 2172220443996
   PubMed Web of Science ®Google Scholar
• GuptaMAGuptaAKThe Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stressActa Derm Venereol19957532402437653188
   PubMed Web of Science ®Google Scholar
• KentGal-AbadieMThe Psoriasis Disability Index – further analysesClin Exp Dermatol19931854144168252760
   PubMed Web of Science ®Google Scholar
• FortuneDGMainCJO’SullivanTMGriffithsCEAssessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress InventoryJ Psychosom Res19974254674759194019
   PubMed Web of Science ®Google Scholar
• FinlayAYKhanGKLuscombeDKSalekMSValidation of Sickness Impact Profile and Psoriasis Disability Index in PsoriasisBr J Dermatol199012367517562265090
   PubMed Web of Science ®Google Scholar
• GronholmPCThornicroftGLaurensKREvans-LackoSMental health-related stigma and pathways to care for people at risk of psychotic disorders or experiencing first-episode psychosis: a systematic reviewPsychol Med Epub2017215
   Web of Science ®Google Scholar
• SchnyderNPanczakRGrothNSchultze-LutterFAssociation between mental health-related stigma and active help-seeking: systematic review and meta-analysisBr J Psychiatry Epub201722
   Web of Science ®Google Scholar
• RubakSSandbaekALauritzenTChristensenBMotivational interviewing: a systematic review and meta-analysisBr J Gen Pract20055551330531215826439
   PubMed Web of Science ®Google Scholar
• ZomahounHTGuenetteLGregoireJPEffectiveness of motivational interviewing interventions on medication adherence in adults with chronic diseases: a systematic review and meta-analysisInt J Epidemiol Epub20161117
   Web of Science ®Google Scholar
• KoblenzerCSKoblenzerPJChronic intractable atopic eczema. Its occurrence as a physical sign of impaired parent-child relationships and psychologic developmental arrest: improvement through parent insight and educationArch Dermatol198812411167316773052306
   PubMedGoogle Scholar
• MorawskaAMitchellAEBurgessSFraserJEffects of Triple P parenting intervention on child health outcomes for childhood asthma and eczema: randomised controlled trialBehav Res Ther201683354427295179
   PubMed Web of Science ®Google Scholar
• WilliamsDHManagement of atopic dermatitis in children; control of maternal rejection factorArch Dermatol Syphilol1951635545560
   Google Scholar
• BrownDGBettleyFRPsychiatric treatment of eczema: a controlled trialBr Med J1971257647297345090759
   PubMed Web of Science ®Google Scholar
• FordhamBGriffithsCEBundyCA pilot study examining mindfulness-based cognitive therapy in psoriasisPsychol Health Med Epub201441
   Web of Science ®Google Scholar
• FortuneDGRichardsHLKirbyBBowcockSMainCJGriffithsCEA cognitive-behavioural symptom management programme as an adjunct in psoriasis therapyBr J Dermatol2002146345846511952546
   PubMed Web of Science ®Google Scholar
• AltafKMohandasPMarshallCTaylorRBewleyAManaging patients with delusional infestations in an integrated psychodermatology clinic is much more cost effective than a general dermatology or primary care settingBr J Dermatol Epub2016928
   Web of Science ®Google Scholar
• BewleyAPDelusional infestationPresented at: American Academy of Dermatology Annual MeetingMarch 5, 2017Orlando, FL
   Google Scholar
• FreudenmannRWLeppingPSecond-generation antipsychotics in primary and secondary delusional parasitosis: outcome and efficacyJ Clin Psychopharmacol200828550050818794644
   PubMed Web of Science ®Google Scholar
• HoughtonDCMaasJTwohigMPComorbidity and quality of life in adults with hair pulling disorderPsychiatry Res2016239121927137957
   PubMed Web of Science ®Google Scholar
• JuergensSAlprazolam and diazepam: addiction potentialJ Subst Abuse Treat199181–243512051498
   PubMed Web of Science ®Google Scholar
• RemickRAKellerFDBuchananRAGibsonREFlemingJAA comparison of the efficacy and safety of alprazolam and desipramine in depressed outpatientsCan J Psychiatry19883375905943058290
   PubMed Web of Science ®Google Scholar
• SinghANNairNPSuranyi-CadotteBSchwartzGLizondoEA double blind comparison of alprazolam and amitriptyline hydrochloride in the treatment of nonpsychotic depressionCan J Psychiatry19883332182223289717
   PubMed Web of Science ®Google Scholar
• WarnerMDPeabodyCAWhitefordHAHollisterLEAlprazolam as an antidepressantJ Clin Psychiatry19884941481503281931
   PubMed Web of Science ®Google Scholar
• WangSMKimJBSakongJKThe efficacy and safety of clonazepam in patients with anxiety disorder taking newer antidepressants: a multicenter naturalistic studyClin Psychopharmacol Neurosci201614217718327121429
   PubMed Web of Science ®Google Scholar
• UhlenhuthEHBuspirone: a clinical review of a new, non-benzodiazepine anxiolyticJ Clin Psychiatry19824312 Pt 21091166130067
   PubMed Web of Science ®Google Scholar
• GammansREMayolRFMackenthunAVSokyaLFThe relationship between buspirone bioavailability and dose in healthy subjectsBiopharm Drug Dispos1985621391452860931
   PubMed Web of Science ®Google Scholar
• TillerJWThe new and newer antianxiety agentsMed J Aust198915111–126977012574409
   PubMed Web of Science ®Google Scholar
• KavanMGElsasserGBaroneEJGeneralized anxiety disorder: practical assessment and managementAm Fam Phys2009799785791
   Web of Science ®Google Scholar
• BielskiRJBoseAChangCCA double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorderAnn Clin Psychiatry2005172656916075658
   PubMedGoogle Scholar
• DavidsonJRBoseAKorotzerAZhengHEscitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose studyDepress Anxiety200419423424015274172
   PubMed Web of Science ®Google Scholar
• DavidsonJRBoseAWangQSafety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorderJ Clin Psychiatry200566111441144616420082
   PubMed Web of Science ®Google Scholar
• HarrisBASherertzEFFlowersFPImprovement of chronic neurotic excoriations with oral doxepin therapyInt J Dermatol19872685415433679664
   PubMed Web of Science ®Google Scholar
• FigueiredoARibeiroCAGoncaloMAlmeidaLPoiares-BaptistaATeixeiraFMechanism of action of doxepin in the treatment of chronic urticariaFundam Clin Pharmacol1990421471582141000
   PubMed Web of Science ®Google Scholar
• LawlorFGreavesMWDie Entwicklung neuer Strategien der Urticariathera - pie als ein Ergebnis klinisch orientierter Forschung [The development of recent strategies in the treatment of urticaria as a result of clinically oriented research]Zeitschrift fur Hautkrankheiten19906511727 Danish1970207
   PubMedGoogle Scholar
• RaoKSMenonPKHilmanBCSebastianCSBairnsfatherLDuration of the suppressive effect of tricyclic antidepressants on histamine-induced wheal-and-flare reactions in human skinJ Allergy Clin Immunol1988825 Pt 17527572903876
   PubMed Web of Science ®Google Scholar
• LeuchtSSteimerWKreuzSAbrahamDOrsulakPJKisslingWDoxepin plasma concentrations: is there really a therapeutic range?J Clin Psychopharmacol200121443243911476128
   PubMed Web of Science ®Google Scholar
• WardNGBloomVLWilsonLRaskindMRaisysVADoxepin plasma levels and therapeutic response in depression: preliminary findingsJ Clin Psychopharmacol1982221261287076877
   PubMed Web of Science ®Google Scholar
• EntsuahRUptonGVRudolphREfficacy of venlafaxine treatment in depressed patients with psychomotor retardation or agitation: a metaanalysisHuman Psychopharmacol1995103195200
   Web of Science ®Google Scholar
• SinghABBousmanCANgCHByronKBerkMPsychomotor depressive symptoms may differentially respond to venlafaxineInt Clin Psychopharmacol201328312112623442739
   PubMed Web of Science ®Google Scholar
• BaghaiTCEserDMollerHJEffects of different antidepressant treatments on the core of depressionDialogues Clin Neurosci200810330932018979944
   PubMedGoogle Scholar
• CiprianiAFurukawaTASalantiGComparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysisLancet2009373966574675819185342
   PubMed Web of Science ®Google Scholar
• FlamentMFLaneRMZhuRYingZPredictors of an acute antidepressant response to fluoxetine and sertralineInt Clin Psychopharmacol199914525927510529069
   PubMed Web of Science ®Google Scholar
• GuptaRKMollerHJSt. John’s Wort. An option for the primary care treatment of depressive patients?Eur Arch Psychiatry Clin Neurosci2003253314014812904978
   PubMed Web of Science ®Google Scholar
• KasperSHypericum perforatum – a review of clinical studiesPharmacopsychiatry200134Suppl 1S51S5511518077
   PubMed Web of Science ®Google Scholar
• LaakmannGSchuleCBaghaiTKieserMSt. John’s wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacyPharmacopsychiatry199831Suppl 154599684948
   PubMed Web of Science ®Google Scholar
• UebelhackRGruenwaldJGraubaumHJBuschREfficacy and tolerability of hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trialAdv Ther200421426527515605620
   PubMed Web of Science ®Google Scholar
• MarkowitzJSDonovanJLDeVaneCLEffect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzymeJAMA2003290111500150413129991
   PubMed Web of Science ®Google Scholar
• LevinECGielerUDelusions of parasitosisSemin Cutan Med Surg2013322737724049963
   PubMed Web of Science ®Google Scholar
• MunroAMonosymptomatic hypochondriacal psychosisBr J Psychiatry Suppl1988237403072051
   PubMedGoogle Scholar
• PatelVKooJYDelusions of parasitosis; suggested dialogue between dermatologist and patientJ Dermatolog Treat201526545646025490455
   PubMed Web of Science ®Google Scholar
• FlannSShotboltJKesselBThree cases of delusional parasitosis caused by dopamine agonistsClin Exp Dermatol201035774074220345988
   PubMed Web of Science ®Google Scholar
• KolleMLeppingPKassubekJSchonfeldt-LecuonaCFreudenmannRWDelusional infestation induced by piribedil add-on in Parkinson’s diseasePharmacopsychiatry201043624024220614418
   PubMed Web of Science ®Google Scholar
• MarshallCLWilliamsVEllisCTaylorREBewleyAPDelusional infestation may be caused by recreational drug usage in some patients, but they may not disclose their habitClin Exp Dermatol2017421414527935634
   PubMed Web of Science ®Google Scholar
• AvnstorpCHamannKJepsenPWParasitforrykthed behandlet med pimozid (Orap) [Delusions of parasite infestation treated with pimozide (Orap)]Ugeskrift for laeger19801423421912192 German7423641
   PubMedGoogle Scholar
• DamianiJTFlowersFPPierceDKPimozide in delusions of parasitosisJ Am Acad Dermatol1990222 Pt 13123132312815
   PubMed Web of Science ®Google Scholar
• HamannKAvnstorpCDelusions of infestation treated by pimozide: a double-blind crossover clinical studyActa Derm Venereol198262155586175138
   PubMed Web of Science ®Google Scholar
• LorenzoCRKooJPimozide in dermatologic practice: a comprehensive reviewAm J Clin Dermatol20045533934915554735
   PubMed Web of Science ®Google Scholar
• WinslowRSStillnerVCoonsDJRobisonMWPrevention of acute dystonic reactions in patients beginning high-potency neurolepticsAm J Psychiatry198614367067102872822
   PubMed Web of Science ®Google Scholar
• HuberMLeppingPPychaRKarnerMSchwitzerJFreudenmannRWDelusional infestation: treatment outcome with antipsychotics in 17 consecutive patients (using standardized reporting criteria)Gen Hosp Psychiatry201133660461121762999
   PubMed Web of Science ®Google Scholar
• TrabertW100 years of delusional parasitosis. Meta-analysis of 1,223 case reportsPsychopathology19952852382468559947
   PubMed Web of Science ®Google Scholar
• HuangWLChangLRAripiprazole in the treatment of delusional parasitosis with ocular and dermatologic presentationsJ Clin Psychopharmacol201333227227323422386
   PubMed Web of Science ®Google Scholar
• LadizinskiBBusseKLBhutaniTKooJYAripiprazole as a viable alternative for treating delusions of parasitosisJ Drugs Dermatol20109121531153221120263
   PubMed Web of Science ®Google Scholar
• BakMFransenAJanssenJvan OsJDrukkerMAlmost all anti-psychotics result in weight gain: a meta-analysisPLoS One201494e9411224763306
   PubMed Web of Science ®Google Scholar
• BarakNBeckYAlbeckJHA randomized, double-blind, placebo-controlled pilot study of betahistine to counteract olanzapine-associated weight gainJ Clin Psychopharmacol201636325325627028981
   PubMed Web of Science ®Google Scholar
• BarakNBeckYAlbeckJHBetahistine decreases olanzapine-induced weight gain and somnolence in humansJ Psychopharmacol201630323724126839321
   PubMed Web of Science ®Google Scholar
• LianJHuangXFPaiNDengCAmeliorating antipsychotic-induced weight gain by betahistine: mechanisms and clinical implicationsPharmacol Res2016106516326892184
   PubMed Web of Science ®Google Scholar
• WongSBewleyAPatients with delusional infestation (delusional parasitosis) often require prolonged treatment as recurrence of symptoms after cessation of treatment is common: an observational studyBr J Dermatol2011165489389621605110
   PubMed Web of Science ®Google Scholar
• BrakouliasVManaging obsessive compulsive disorderAust Prescr201538412112326648639
   PubMedGoogle Scholar
• OstLGRiiseENWergelandGJHansenBKvaleGCognitive behavioral and pharmacological treatments of OCD in children: a systematic review and meta-analysisJ Anxiety Disord201643586927632568
   PubMed Web of Science ®Google Scholar
• WoottonBMRemote cognitive-behavior therapy for obsessive-compulsive symptoms: a meta-analysisClin Psychol Rev20164310311326494179
   PubMed Web of Science ®Google Scholar
• KatzRJDeVeaugh-GeissJLandauPClomipramine in obsessive-compulsive disorderBiol Psychiatry19902854014142207219
   PubMed Web of Science ®Google Scholar
• LeonardHSwedoSRapoportJLCoffeyMCheslowDTreatment of childhood obsessive compulsive disorder with clomipramine and desmethylimipramine: a double-blind crossover comparisonPsychopharmacol Bull198824193953290954
   PubMedGoogle Scholar
• LeonardHLLenaneMCSwedoSERettewDCRapoportJLA double-blind comparison of clomipramine and desipramine treatment of severe onychophagia (nail biting)Arch Gen Psychiatry19914898218271929772
   PubMed Web of Science ®Google Scholar
• SwedoSELeonardHLRapoportJLLenaneMCGoldbergerELCheslowDLA double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling)N Engl J Med198932184975012761586
   PubMed Web of Science ®Google Scholar
• PetersMD2ndDavisSKAustinLSClomipramine: an antiobsessional tricyclic antidepressantClin Pharm1990931651782180623
   PubMedGoogle Scholar
• PigottTAPatoMTBernsteinSEControlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological resultsArch Gen Psychiatry199047109269322222131
   PubMed Web of Science ®Google Scholar
• VittorioCCPhillipsKATreatment of habit-tic deformity with fluoxetineArch Dermatol199713310120312049382557
   PubMedGoogle Scholar
• GouldingJMN-acetylcysteine in trichotillomania: further thoughtsBr J Dermatol201517261683168425640599
   PubMed Web of Science ®Google Scholar
• GrantJEOdlaugBLKimSWN-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled studyArch Gen Psychiatry200966775676319581567
   PubMed Web of Science ®Google Scholar
• OzcanDSeckinDN-Acetylcysteine in the treatment of trichotillomania: remarkable results in two patientsJ Eur Acad Dermatol Venereol20163091606160827146087
   PubMed Web of Science ®Google Scholar
• TaylorMBhagwandasKN-acetylcysteine in trichotillomania: a panacea for compulsive skin disorders?Br J Dermatol201417151253125524773206
   PubMed Web of Science ®Google Scholar
• RothbartRAmosTSiegfriedNPharmacotherapy for trichotillomaniaCochrane Database Syst Rev201311Cd007662
   PubMed Web of Science ®Google Scholar
• RingDSInexpensive solution for habit-tic deformityArch Dermatol2010146111222122321079056
   PubMedGoogle Scholar
• BowenCBidingerJHivnorCHooverAHenningJSAllergic contact dermatitis to 2-octyl cyanoacrylateCutis201494418318625372253
   PubMed Web of Science ®Google Scholar
• DavisMDStuartMJSevere allergic contact dermatitis to dermabond prineo, a topical skin adhesive of 2-octyl cyanoacrylate increasingly used in surgeries to close woundsDermatitis2016272757626983096
   PubMed Web of Science ®Google Scholar
• LefevreSValoisATruchetetFAllergic contact dermatitis caused by Dermabond((R))Contact Dermatitis201675424024127620119
   PubMed Web of Science ®Google Scholar